A Bioequivalence study of a randomized,
Sponsors
Bio-innova and Synchron.Co.,Ltd
Conditions
Bioequivalence study
Bioequivalence
EtoricoxibBioequivalence study
Bioequivalence study
AmisulprideBioequivalence study
Bioequivalence study
EtoricoxibBioequivalence study in healthy volunteers
Bioequivalence
Losartan
Hydrochlorothiazide
Early Phase 1
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Amisulpride FCT (400 mg) relative to Solian(R) 400 mg in healthy Thai volunteers under fasting condition
Active, not recruitingTCTR20190712004
Start: 2019-08-05Target: 46Updated: 2026-03-30
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of NUCOXIA 120 (Etoricoxib 120 mg tablets) relative to Arcoxia® 120 mg (Etoricoxib, MSD) tablets in healthy Thai volunteers under fasting condition
Active, not recruitingTCTR20191022001
Start: 2019-12-02Target: 28Updated: 2026-03-30
Phase 1
A Bioequivalence study of a randomized, open-label, 4-period, 2-treatment, 2-sequence, replicate, crossover study of Losartan 100 mg + Hydrochlorothiazide 25 mg tablets relative to Fortzaar® 100/25 mg tablets in healthy Thai volunteers under fasting condition
Active, not recruitingTCTR20170629005
Start: 2017-09-01Target: 40Updated: 2026-03-30
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Etoricoxib film-coated tablets, 120 mg relative to Arcoxia® 120 mg tablets in healthy Thai volunteers under fasting condition
Active, not recruitingTCTR20181002006
Start: 2019-01-07Target: 24Updated: 2026-03-30